Led by San Diego-based Corporate partner Mike Hird and New-York-based M&A partner Jarrod Murphy, a team of Pillsbury lawyers is representing BioLegend, a leading global provider of life science antibodies and reagents, in its $5.25 billion acquisition by PerkinElmer, Inc.

BioLegend, a privately-held maker of biomedical research tools, provides antibodies and reagents to laboratories at universities and pharmaceutical companies studying cells, proteins and genetics. BioLegend will expand PerkinElmer’s existing life science franchise into new segments and its state-of-the-art campus in San Diego will become PerkinElmer’s global Center of Excellence for research reagent content development for the combined company.

Read more on the transaction here.

Pillsbury has represented BioLegend since its incorporation in 2002. In addition to Hird and Murphy, the Pillsbury team advising BioLegend in this transaction includes Corporate partners Gabriella Lombardi and Richard Blaylock, counsel Julie Park, associates Tara Shankar and Hana Cho, senior law clerk Harriet McCartin and senior legal analyst Rory O’Neill; Tax partner Nora Burke; Finance partners Joel Simon and Joe Fastiggi; Antitrust attorneys Alvin Dunn and Evan Storm; Regulatory partner Nancy Fischer, counsel Matt Rabinowitz and associate Zach Rozen; Executive Compensation & Benefits partner Cindy Schlaefer and senior law clerk Kevin Meil; Employment Law partner Paula Weber and senior counsel Laura Latham; Litigation special counsel Andrea Milano; and Intellectual Property special counsel Michelle Mehok.